ClinicalTrials.gg
CompletedNCT01767428Updated Jan 14, 2013

Pharmacokinetic Study to Compare Two Formulations of Paracetamol

A Phase 1 interventional study of Paracetamol in Fever, Headache Disorders and Pain, sponsored by GlaxoSmithKline. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-14.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A pharmacokinetic study in healthy volunteers comparing two formulations of paracetamol fast release in fasted state.

02

Conditions studied

  • Fever
  • Headache Disorders
  • Pain
03

In context

Fever

605 studies on the registry are indexed under Fever; 98 are open to participants now.

This study's enrollment of 30 is below the median of 100 across 386 interventional studies indexed under Fever.

Browse Fever studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,647 studies on the registry; 118 are open to participants now.

Of its 264 completed or terminated interventional studies of FDA-regulated products, 239 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers aged 18-55yrs willing to give written informed consent for the study
  • BMI must be within the range 18.5 - 24.9 kg/m\^2
  • Participant with a minimum weight of 50 kg

Exclusion criteria

Exclusion Criteria:

  • Participant with current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)
  • Participant with known or suspected intolerance or hypersensitivity to the study materials
  • Participant who are vegetarian
  • Participant smoking more than five cigarettes a day
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Experimental Paracetamol Tablet

    Experimental paracetamol tablet (500 milligrams \[mg\]) administered with 240 milliliters (mL) of water.

    Drug: Paracetamol

  • Active comparator
    Standard Paracetamol Tablet (500 mg)

    Standard paracetamol tablet (500 mg) administered with 240 mL of water.

    Drug: Paracetamol

Interventions

  • 500 mg immediate release paracetamol formulations

06

What researchers measure

Primary outcomes

  1. AUC (0-inf)

    Area under the plasma concentration time curve from zero and extrapolated to infinite time.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

  2. Cmax

    Maximum plasma concentration of paracetamol.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

  3. AUC (0-t)

    Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Secondary outcomes

  1. Tmax

    Time taken to reach maximum plasma concentration of paracetamol.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01767428
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Apr 2010
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Jan 14, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion